The DOI matches its Crossref record.
Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine
Abstract
From 1969 to 1990 there were 309 patients with differentiated thyroid carcinoma (241 papillary and 68 follicular) treated with radioactive iodine for functioning node metastases alone (n=191) or distant metastases (n=118) with or without node metastases. These patients represented 32.7% of 945 patients treated in our institution during the same period. Initial treatment included near‐total thyroidectomy and 131 I ablation of postsurgical thyroid residue, followed by L‐thyroxine suppressive therapy. At the end of follow‐up (mean 5.8 years), 146 patients (76.4%) in the group with nodal metastases were considered cured, as assessed by clinical and laboratory evaluation including whole body scan (WBS) and serum thyroglobulin (Tg) levels; 32 patients (16.7%) had persistent disease. Loss of 131 I uptake in persistent metastatic lesions occurred in five patients (2.6%), and newly developed distant metastases occurred in eight patients (4.2%). Of the patients with distant metastases, 36.4% were cured by 131 I. Distant metastases from papillary carcinomas had a higher cure rate than follicular carcinomas (p<0.01). The metastases of four patients (5.2%) lost the property to take up radioiodine. Lung and bone metastases detectable by WBS but not by radiography were most likely to be cured by 131 I. The overall survival at the end of follow‐up was 95.8% in patients with only lymph node metastases and 76.0% in those with distant metastases. Tumor‐related deaths were 3.6% and 23.7%, respectively. Our data indicate that 131 I therapy is highly effective in the treatment of lymph node metastases from differentiated thyroid carcinoma. To a variable extent, distant metastases may also benefit from radioiodine therapy, definitive cure being much more likely during the early phase of metastatic involvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976
Self-citationGuidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 727
Current practice in patients with differentiated thyroid cancer
Schlumberger, M., & Leboulleux, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00448-z · Cited by 342
Papillary and follicular thyroid carcinoma
Schlumberger, M. J., & Torlantano, M. (2000) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2000.0105 · Cited by 278
Bone metastases from differentiated thyroid carcinoma
Muresan, M. M., Olivier, P., Leclere, J., Sirveaux, F., Brunaud, L., Klein, M., Zarnegar, R., & Weryha, G. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0229 · Cited by 260
New therapeutic approaches for metastatic thyroid carcinoma
Baudin, E., & Schlumberger, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70034-7 · Cited by 143
Huang, S.-H., Wang, P.-W., Huang, Y.-E., Chou, F.-F., Liu, R.-T., Tung, S.-C., Chen, J.-F., Kuo, M.-C., Hsieh, J.-R., & Hsieh, H.-H. (2006) · Thyroid · doi:10.1089/thy.2006.16.1273 · Cited by 32
Metadata
- Authors
- Pacini, F., Cetani, F., Miccoli, P., Mancusi, F., Ceccarelli, C., Lippi, F., Martino, E., & Pinchera, A.
- Venue
- World Journal of Surgery
- Publisher
- Wiley
- Published
- 1994-07
- Volume
- 18
- Issue
- 4
- Pages
- 600-604
- ISSN
- 0364-2313 (ISSN-L)
- 1432-2323
- OpenAlex
- W2014664476
- Cited by
- 175
- References
- 0
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.